There are few data on the impact of antiretroviral therapy (ART) regimen factors on adherence in ART-naïve HIV patients on contemporary once-or twice-daily regimens. Ninety-nine newly diagnosed patients in a prospective observational cohort study completed a visual analogue scale to assess their ART adherence. Adherence by type of ART and dosing frequency were compared by Brown -Mood median tests. Participants taking once-daily regimens had higher adherence (n ¼ 70, 99.5%) compared with participants taking twice-daily regimens (n ¼ 29, 94%; P ¼ 0.01). Adherence of participants taking the fixed dose combination efavirenz -emtricitabine -tenofovir (n ¼ 34, 100%) compared with those taking once-daily regimens of two or more pills was no different (n ¼ 36, 99.3%; P ¼ 0.34). Among a cohort of newly diagnosed ART-naïve patients, once-daily dosing of ART resulted in higher adherence than twice-daily dosing. Pill burden among once-daily regimens did not predict adherence, suggesting that factors other than pill burden should drive regimen selection.
INTRODUCTION
Combination antiretroviral therapy (cART) provides immunological and virological benefits to patients with HIV. However, such benefits cannot be achieved without medication adherence. In the early years of the antiretroviral therapy era, cART consisted of complicated regimens with high pill burden and frequent dosing. Newer regimens consist of fixed dose combination pills. In October 2004, the Department of Health and Human Services treatment guidelines recommended use of efavirenz (EFV) with emtricitabine (FTC) and tenofovir (TDF) in HIV-treatment naïve patients as one of the preferred regimens. 1 Thereafter, a fixed dose combination one pill, once-daily regimen of EFV/FTC/TDF was developed.
Several studies have shown that characteristics of antiretroviral regimens can affect patients' medication adherence. A recent meta-analysis of 11 randomized, controlled trials of different cART regimens found that adherence was higher with once-daily regimens (þ2.9%; 95% confidence interval 1.0-4.8%; P , 0.003) than twice-daily regimens, with a more profound effect seen at the time of treatment initiation. 2 The fixed dose combination EFV/FTC/TDF was not studied in comparison to other once-daily regimens in that meta-analysis. Participants in a prospective cohort study had higher adherence on cART with low dosing frequencies (the lowest being twice daily) but not with low pill burden. 3 A five-month observational cohort study of participants who had been on cART for more than four months found that a lower number of pills (P ¼ 0.02) and fewer daily doses (P ¼ 0.02) were associated with higher adherence as measured by the Adult AIDS Clinical Trial Group (AACTG) four-day self-report instrument. 4 In addition, a prospective observational study in Italy found higher AACTG four-day self-report adherence for participants with a lower number of pills in their prescribed cART regimen (P ¼ 0.02) and a lower number of required daily doses (P ¼ 0.04). 5 Fixed dose combination EFV/FTC/TDF was not available in the latter three studies. Bangsberg et al. 6 recently conducted a prospective observational cohort study in primarily cART-experienced homeless participants for six months and found that adherence by unannounced pill count was higher in participants who took fixed dose combination EFV/FTC/TDF compared with participants taking any other regimen (P , 0.01). Airoldi et al. 7 found that patients who were first treated with FTC þ TDF þ EFV or lamivudine (3TC) þ TDF þ EFV and had a HIV-RNA ,50 copies/mL and were then switched to fixed dose combination EFV/FTC/TDF had better adherence after the switch (93.8% versus 96.1%, respectively; P , 0.01). These studies, including the studies in the meta-analysis, did not assess adherence to contemporary cART regimens (including fixed dose combination EFV/FTC/ TDF) in newly diagnosed, cART-naïve patients. Whether a one-pill once-daily regimen promotes higher adherence than other once-daily regimens in cART-naïve patients is unknown. We report the adherence to contemporary cART regimens of newly diagnosed, cART-naïve participants in an 18-month prospective cohort study.
PATIENTS AND METHODS

Study design, participants and setting
We conducted a prospective, observational cohort study of patients newly diagnosed with HIV infection in Houston, TX, USA. Details of screening and enrollment into the Attitudes and Beliefs and the Steps of HIV Care study (the Steps study) are outlined by Bhatia et al. 8 Participants completed an interviewer-administered questionnaire at baseline and every three months for up to 18 months. These questionnaires were generally completed outside of the clinical setting. The questionnaires included items on demographics, HIV risk factors and incarceration history, as well as a visual analogue scale (VAS) adherence measure for each of their HIV medications if they had been prescribed them. 9 Participants did not undergo standardized adherence counselling as part of the research protocol. Most patients starting cART in the clinic receive adherence counselling as part of routine care from their provider and either a nurse adherence counsellor or a clinical pharmacist. Laboratory data from routine care were retrieved, and medical records were reviewed to verify participants' cART regimens.
Outcome measures and data analysis
For 30-day VAS adherence, the location of the 'X' that the participant wrote on the response scale was converted to a per cent. For example, if they placed an 'X' at the 50% mark on the scale for a medication, their adherence for that medication would be recorded as 50%. 9 The mean adherence for all of the HIV medications in a participant's regimen was calculated at each study time point. The median adherence was then computed for all of the adherence assessments a participant completed over time.
Adherence was censored at a participant's first change in cART regimen or last VAS measurement, whichever came first, as no further data points for adherence were available. As the adherence data were not normally distributed, median rather than mean adherence values were used. The Brown-Mood statistical test was used, as it is more robust against outliers in data compared with the Kruskal-Wallis test. 10 We used generalized estimating equations to conduct adjusted analyses to account for the repeated measures design of the study. The outcome variable was dichotomized at 99-100% or ,99%, and analyses were adjusted for gender, race, age, education level, income, CD4 count at baseline, type of insurance, employment status and place of diagnosis.
At the time of our study, HIV viral load (VL) assays with a lower limit of detection of 400 and 50 copies/mL (c/mL) were both in use at our clinic. To avoid misclassifying participants, we dichotomized VL results as either ,400 c/mL or !400 c/ mL. We used the latest HIV VL that was at least 90 days after a participant started cART but was not 30 days or more after a change in cART. Rates of achieving an undetectable VL for different dosing frequencies and pill burden were compared using Fisher's exact tests.
The study was approved by the institutional review boards of Baylor College of Medicine and The University of Texas Health Science Center at Houston. All participants provided written informed consent.
RESULTS
Ninety-nine of 184
Steps study participants contributed adherence data to this analysis whereas 76 contributed VL data. The remaining participants were not prescribed cART during the study, died or were lost to follow-up before contributing adherence data. Characteristics of the Steps study participants in the present analyses are shown in Table 1 . The majority of the participants were men, ,50 years old, African-American or Hispanic, had no high school degree and had relatively low incomes. The median (interquartile range [IQR]) baseline HIV VL was 5.32 log 10 c/mL (4.90, 5.73), and the median (IQR) baseline CD4 cell count was 135 cells/mm 3 (36, 271).
Forty-seven (47%) participants were on a non-nucleoside reverse transcriptase inhibitor (NNRTI) and 50 (51%) participants were on a boosted protease inhibitor. Seventy participants (71%) were on a once-daily regimen, including 34 (34%) participants who were taking the fixed dose combination EFV/FTC/TDF and 36 (36%) participants who were taking a once-daily regimen that included more than one pill. Twenty-nine participants (29%) were on a twice-daily regimen. Accounting for gender, age, race/ethnicity, education, income, type of insurance and place of HIV diagnosis, no differences were found between participants who were prescribed an NNRTI or a protease inhibitor, a once-daily regimen and a twice-daily regimen, or a one-pill once-daily regimen and a .one-pill once-daily regimen. Of the participants taking more than one pill a day, seven participants were taking two pills a day, 16 participants were taking three pills a day, 15 participants were taking four pills a day and 17 participants were taking five pills a day ( Table 1 ). The median number of days between when participants started cART and when they changed cART or completed their last VAS was 371 days (IQR 182, 488). The median number of VAS completed per participant was three. The median VAS adherence for participants taking oncedaily regimens was 99.5% (IQR 90.0, 100.0), which was significantly higher than the adherence of participants taking twicedaily regimens (94.0%; IQR 90.0, 99.3; P ¼ 0.01; Figure 1 ). Median VAS adherence for participants taking fixed dose combination EFV/FTC/TDF was 100.0% (IQR 93.0, 100.0); for participants taking once-daily regimens that were more than one pill, it was 99.3% (IQR 90.0, 100.0). There was no significant difference in VAS adherence between participants taking fixed dose combination EFV/FTC/TDF and participants taking oncedaily regimens of more than one pill (P ¼ 0.34). Adherence was lower in the twice-daily group compared with the one-pill once-daily and more than one-pill once-daily groups, after controlling for gender, race, age, education level, income, CD4 count at baseline, type of insurance, employment status and place of diagnosis (Table 2 ; P ¼ 0.01). We dichotomized adherence as 99-100% and ,99% given that the overall median adherence of our study population was 97.5% (IQR 90.0, 100.0).
The median number of days between when participants started cART and their outcome VL measurement was 352 days (IQR 179, 505). Participants who had 99 -100% adherence by VAS were slightly more likely to have virological suppression (n ¼ 38, 84% suppressed) compared with participants with less than 99% adherence (n ¼ 36, 64% suppressed, P ¼ 0.06). There was no statistically significant difference in viral suppression between participants taking once-daily regimens (n ¼ 42, 79.3% suppressed) and participants taking twice-daily regimens (n ¼ 14; 60.9% suppressed; P ¼ 0.15). There was also no statistically significant difference in viral suppression between participants taking fixed dose combination EFV/ FTC/TDF (n ¼ 23, 82.1% suppressed) and participants taking once-daily regimens of more than one pill (n ¼ 19; 76.0% suppressed; P ¼ 0.74), and between participants taking one-pill EFV/FTC/TDF and participants taking all other regimens (n ¼ 33; 68.6% suppressed; P ¼ 0.28).
DISCUSSION
In this study of participants recently diagnosed with HIV infection, once-daily dosing of cART resulted in higher adherence than twice-daily dosing, as measured by a VAS. In contrast, among participants on once-daily regimens, adherence to a one-pill regimen was no different than adherence to regimens with more than one pill. These results suggest that pill burden is not an important factor in determining adherence to contemporary once-daily cART regimens in cART-naïve patients.
Several studies have shown that participants exhibit higher adherence with once-daily dosing of antiretrovirals compared with twice-daily dosing. 2, 4, 5, 11 Some studies have also shown that a lower pill burden results in higher adherence. 4 -6 Specifically, Airoldi et al. 7 found that patients who had HIV-RNA ,50 copies/mL on a once-daily regimen of more than one pill and were then switched to fixed dose combination EFV/FTC/TDF had better adherence after the switch (93.8% versus 96.1%, respectively; P , 0.01). To our knowledge, our study is the first to compare adherence between one-pill oncedaily regimens and once-daily regimens of more than one pill in cART-naive patients. We expected that therapy with a single tablet once daily would result in higher adherence. Somewhat surprisingly, we found no differences in adherence between the once-daily regimens. Our data support once-daily dosing, but do not support the hypothesis that a one-pill oncedaily dose is associated with higher adherence than other oncedaily regimens.
Although our study participants who took cART once daily had higher rates of virological suppression compared with participants taking cART twice daily, the difference was not statistically significant (P ¼ 0.15), although this result is likely due to our small sample size. Parienti et al. 2 also found no significant difference in the proportion of participants who achieved HIV -RNA levels of ,50 c/mL (P ¼ 0.21) between participants taking once-daily versus twice-daily regimens. Bangsberg et al. 6 found that viral suppression was higher in participants taking fixed dose combination EFV/FTC/TDF (69%) compared with participants taking any other regimen (46%, P ¼ 0.02) but did not compare once-daily versus twicedaily regimens exclusively.
We also did not find a statistically significant difference in achievement of virological suppression based on pill burden, 6 found that viral suppression was higher in participants taking fixed dose combination EFV/FTC/TDF (69%) compared with participants taking any other regimen with more than one pill (46%, P ¼ 0.02). Together, these results and the results of this study suggest that pill burden for contemporary regimens is low enough that, among once-daily regimens, it is not a major factor in determining adherence or viral suppression as long as it is below some as yet undefined threshold.
This study has several limitations. Adherence was measured by self-report rather than more objective measures such as pharmacy refill data or Medication Event Monitoring System caps. These data were available for a subset of participants, but not enough to produce reliable estimates for the questions addressed in the present set of analyses. As noted earlier, only 99 participants of the entire Steps cohort of 184 participants contributed to the analysis, and only 76 of 99 participants were included in the viral suppression analyses, thus decreasing our ability to detect small differences in adherence and virological suppression. Some participants did not have a VL in their medical record after starting cART because they dropped out of or transferred care. The generalizibility of our results may be impacted by the fact that participants who were not prescribed cART during the study, died or were lost to follow-up are not included in these analyses, Furthermore, adherence in participants was reported to be very high, which may not have been the case for the excluded participants. The high reported adherence is likely partly due to patients overstating their adherence, possibly due to social desirability. Finally, these data are observational, and participants should have been prescribed regimens that fit their lifestyle and clinical needs best. Patients thought to be less likely to adhere may have been placed on less demanding regimens from the start, thus confounding later adherence results. In that sense, these data represent what is achievable in routine HIV care with contemporary cART regimens.
AIDS Drug Assistance Programs (ADAPs) are state-run programmes that provide HIV medications for low income, uninsured and underinsured individuals in the United States. As ADAP client enrollment continues to increase, cost-cutting measures have had to be implemented. Each ADAP has adopted its own formulary, and 24 ADAPs do not cover all FDA-approved antiretrovirals in all drug classes. 14 High drug costs are a concern in other developed and developing countries as well. 15 Our study results suggest that fixed dose combination pills are not as critical as dosing schedule in promoting excellent adherence. Cost containment strategies that rely on generic drugs not available in fixed dose combination pills will, however, need careful evaluation for their clinical impact. This is the first study to our knowledge to examine the effect of regimen factors on adherence in exclusively newly diagnosed, cART-naïve participants on contemporary cART regimens that include fixed dose combination EFV/FTC/TDF. We found that once-daily dosing was associated with greater adherence than twice-daily dosing. In contrast, the number of pills did not predict adherence among participants on a oncedaily regimen. When possible, once-daily dosing may be the recommended dosing schedule, compared with twice-daily dosing. Among once-daily regimens, factors other than pill burden (e.g. side-effects, drug interactions, daily schedule and patient preference) should drive regimen selection. 
